Base metrics
- Operating margin
- 39.7%
- Interest coverage
- 6.2x
- Return on equity (ROE)
- 22.5%
Catalyst Pharmaceuticals financial statements
NASDAQ:CPRX · Nasdaq$31.49+0.00%
2026-07-16 closeCatalyst Pharmaceuticals's published financial data is dated 2026-10-04. 2024 revenue was $492M. 2024 operating profit was $195M.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 12.68
Distress
Grey
Safe
- Altman Z''
- 12.68
- Beneish M-Score
- -2.80
- Sloan accrual
- -8.92%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
7/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score7/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
TolerableInterest coverageBase 6.2x adverse case 5.5x
Return on equity (ROE)Base 22.5% adverse case 19.1%
Revenue −15%
TolerableInterest coverageBase 6.2x adverse case 5.3x
Return on equity (ROE)Base 22.5% adverse case 18.5%
Interest rate +2pp
TolerableInterest coverageBase 6.2x adverse case 5.8x
Return on equity (ROE)Base 22.5% adverse case 22.2%
Interest coverage limit
Current margin 33.3ppInterest coverage limit at an operating margin of 6.4%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy